In 2021,138,825 people died from COPD in the U.S., making it the sixth overall leading cause of death and the fifth ...

China approves GSK's Nucala for chronic rhinosinusitis with nasal polyps, adding to its existing uses in asthma and other ...

For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol, according to ...

An 84-year-old man with heart conditions endured an agonising three-hour wait for an ambulance while lying on his damp ...

Sep. 10, 2024 — A scientific team has created a preclinical blood test to identify adults most likely to develop severe respiratory conditions, including chronic obstructive pulmonary disease ...

Eligible patients had COPD, were ages 40 or older, and were new initiators of these inhalers from 2021 to 2023. They were ...

Seek expert support for respiratory issues from pulmonologists. Learn how they diagnose and manage lung diseases for better ...

• Establish a supportive company culture. Business leaders can signal to employees that they should prioritize their ...

They display ... Second Phase 3 Clinical Trial Again Shows Dupilumab Lessens Disease in COPD Patients With Type 2 Inflammation May 20, 2024 — Chronic obstructive pulmonary disease patients with ...

Discover the top 19 most notable drugs approved by the FDA in 2024, including Dupixent for COPD and FluMist for self-administration. See the full list here.

Pegtarazimod is under clinical development by ReAlta Life Sciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury.